参芪扶正注射液联合化疗治疗非小细胞肺癌41例临床观察  

Clinical Observation on Shenqi Fuzheng Injection( 参芪扶正注射液) Combined With Chemotherapy for 41 Cases of Non-Small Cell Lung Cancer

作　　者：王廷祥[1] 钭春凤[1] 

机构地区：[1]浙江医院肿瘤科浙江省杭州市灵隐路12号,浙江省310007

出　　处：《中医杂志》2014年第9期775-777,共3页Journal of Traditional Chinese Medicine

摘　　要：目的观察参芪扶正注射液联合化疗治疗中晚期非小细胞肺癌（NSCLC）的临床疗效及毒副反应。方法将82例中晚期NSCLC患者随机分为试验组和对照组各41例。对照组接受NP方案化疗，长春瑞滨25mg／m^2，静脉滴注，第1天、第8天；顺铂（DDP）40mg／m^2，静脉滴注，第l～3天。试验组接受NP方案同对照组，第1～14天静脉滴注参芪扶正注射液250ml，每日1次。21天为1个周期，两组均治疗2个周期。治疗前后测定T淋巴细胞亚群，采用Kamofsky评分评价患者生活质量，测量肿瘤病灶大小，治疗后评价近期疗效及生活质量疗效，并观察毒副反应。结果试验组近期疗效总有效率为46．34％，对照组为43．90％，两组比较差异无统计学意义（P〉0．05）；试验组生活质量疗效改善率为78．05％，对照组为56．10％，试验组明显高于对照组（P〈0．05）。试验组治疗后CD4＋较治疗前明显升高（P〈0．05）；对照组治疗后CD3＋、CD4＋／CD8＋、CIM＋较治疗前明显降低（P〈0．05）；治疗后试验组CD3＋、CD4＋和CD4＋／CD8＋均明显高于对照组（P〈0．05）。试验组恶心呕吐、白细胞减少发生率明显低于对照组（P〈0．05）。结论参芪扶正注射液联合化疗治疗中晚期NSCLC疗效确切，能提高免疫功能，减轻因化疗引起的毒副反应，改善生活质量。ABSTRACT Objective To observe the efficacy and toxicity of shenqi Fuzheng lnjectmn （参芪扶正注射液）J com bined with chemotherapy for advanced non-small cell lung cancer （NSCLC）. Methods Totally 82 cases of ad vanced NSCLC were randomized into the test group and control group, with 41 in each. The control group was given NP chemotherapy with intravenous infusion of vinorelbine 25mg/m2 on the 1st and 8th day and cisplatin （DDP） 40 mg/m2 from the 1 st to 3rd day. The test group was added with 250 ml Shenqi Fuzheng Injection once daily from the 1st to 14th day. Both groups were treated for two periods with 21 days for one period. The T-lymphocyte subsets were determined before and after treatment. The Karnofsky Performance Status Scale （KPS） was used to evaluate the quali- ty of life （QOL）. The size of tumor lesions was measured. The efficacy and toxicity was evaluated after treatment. Results The recent efficacy of the test group and control group was 46.34% and 43.90% respectively, with no sig- nificant difference between groups （P 〉 0. 05 ）. The improvement rate of QOL in the test group and control group was 78.05% and 56. 10% respectively, with a significant difference between groups （P 〈 O. 05）. The percentage of CD4 ＋ was significantly increased in the test group after treatment （ P 〈 0. 05 ）. The percentages of CD3 ~ and CD4 ＋ and ratio of CD4 ＋/CD8 ＋ in the test group were significantly higher than those in the control group （ P 〈 0. 05 ）. The incidence of nausea, vomiting and leucopenia in the test group was significantly lower than that in the control group （ P 〈 0. 05 ）. Conclusion Shenqi Fuzheng Injection combined with chemotherapy is effective for advanced NSCLC. The combo therapy can improve immune function and QOL and reduce chemotherapy-induced toxicity.

关 键 词：非小细胞肺癌 参芪扶正注射液 生活质量 毒副反应 化学疗法 

分 类 号：R734.2[医药卫生—肿瘤]